达比加群和华法林治疗心房颤动合并脑栓塞的疗效和安全性观察

Efficacy and safety observation of anticoagulant therapy in patients with atrial fibrillation and cerebral embolization

目的分析应用达比加群和华法林治疗心房颤动合并脑栓塞患者的临床效果。方法选取平顶山市第一人民医院2015年7月—2017年7月收治的心房颤动合并脑栓塞患者80例,根据治疗方式不同随机分为达比加群组和华法林组各40例,比较两组临床治疗效果。结果达比加群组总有效率为87.5%,华法林组总有效率为90%,达比加群组治疗后凝血指标凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、国际标准化比值(INR)、纤维蛋白原(FIB)、全血血小板(PLT)与华法林组差异无统计学意义(P>0.05);华法林组治疗后出血率为17.5%,达比加群组出血率5%,组间对比差异有统计学意义(P<0.05)。结论达比加群用于心房颤动合并脑栓塞患者的抗凝治疗中能够获得和华法林基本相同的效果,同时可以降低出血风险,应用安全性更高,更有推广价值。

Objective To analyze the clinical effects of darbigatran and warfarin in anticoagulant therapy for patients with atrial fibrillation combined with cerebral embolism. Methods In our college in July 2015—July 2017 were all between atrial fibrillation combined pump,80 cases of cerebral embolism patients to participate in this study,all patients on the basis of treatment can be divided into darby group and warfarin group,each 40 patients,to compare the clinical therapeutic effect. Results The total effective rate of the group was 87. 5%,the total effective rate was 90% in warfarin group,and the blood coagulation index PT,APTT,INR,FIB,PLT and warfarin group were not different in the tbi group. The hemorrhage rate was 17. 5% after treatment with warfarin group,and 5% of the darbiga group hemorrhage rate. Conclusion Added darby group is used to merge cerebral embolism in the anticoagulant therapy in patients with af can be obtained and the effect of warfarin basic same,can lower the risk of bleeding at the same time,the application security is higher,more promotion value.